World's Best Scientists 2026 revealed!
Thomas F. Pajak

Thomas F. Pajak

D-Index & Metrics

Medicine

D-Index
81
Citations
45156
World Ranking
16371
National Ranking
8237

Overview

Thomas F. Pajak is affiliated with the RTOG Foundation in the United States. The foundation is known for its focus on radiation therapy oncology group research, which suggests Pajak's involvement in areas related to oncology and radiation therapy, though specific fields of study are not explicitly detailed in the available data.

No records of recent papers, frequent co-authors, or common publication venues are listed. This absence limits a detailed understanding of Pajak's specific research contributions or collaborations.

There is no information on books published or main research topics, which further constrains insights into their areas of academic focus or thematic expertise.

Despite the lack of specific bibliographic or thematic data, Thomas F. Pajak's continuous professional affiliation indicates ongoing participation in research activities related to the RTOG Foundation, which is predominantly involved in clinical trials and studies in radiation oncology.

No awards or formal recognitions have been recorded, and Pajak is noted to be currently living.

Best Publications

  • Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)

    James D. Cox;Jo Ann Stetz;Thomas F. Pajak

  • Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

    Arlene A. Forastiere;Helmuth Goepfert;Moshe Maor;Thomas F. Pajak

  • Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

    Jay S. Cooper;Thomas F. Pajak;Arlene A. Forastiere;John Jacobs

  • Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

    Jacques Bernier;Jay S. Cooper;T. F. Pajak;M. Van Glabbeke

  • A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003

    Karen K. Fu;Thomas F. Pajak;Andy Trotti;Christopher U. Jones

  • INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

    Bruce D. Minsky;Thomas F. Pajak;Robert J. Ginsberg;Thomas M. Pisansky

  • Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer

    David P. Kelsen;Robert Ginsberg;Thomas F. Pajak;Daniel G. Sheahan

  • Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.

    M Flam;M John;T F Pajak;N Petrelli

  • Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer

    Arlene A. Forastiere;Qiang Zhang;Randal S Weber;Moshe H. Maor

  • Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

    Jean Bourhis;Jens Overgaard;Helene Audry;Kian K. Ang

  • Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02

    Gerald E. Hanks;Thomas F. Pajak;Arthur Porter;David Grignon

  • Long‐term observations of the patterns of failure in patients with unresectable non‐oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group

    Carlos A. Perez;Thomas F. Pajak;Philip Rubin;Joseph R. Simpson

  • A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.

    J D Cox;N Azarnia;R W Byhardt;K H Shin

  • Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.

    Jay S. Cooper;Qiang Zhang;Thomas F. Pajak;Arlene A. Forastiere

  • Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience.

    Jay S. Cooper;Thomas F. Pajak;Philip Rubin;Leslie Tupchong

  • Diffuse Malignant Mesothelioma: Prospective Evaluation of 69 Patients

    A P Chahinian;T F Pajak;J F Holland;L Norton

  • Prophylactic Extended-Field Irradiation of Para-aortic Lymph Nodes in Stages IIB and Bulky IB and IIA Cervical Carcinomas: Ten-Year Treatment Results of RTOG 79-20

    Marvin Rotman;Thomas F. Pajak;Kwang Choi;Michelle Clery

  • Prognostic Factors in Prostate Cancer

    David G. Bostwick;David J. Grignon;M. Elizabeth H. Hammond;Mahul B. Amin

  • The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns-of-care study

    Rachelle M. Lanciano;Thomas F. Pajak;Karen Martz;Gerald E. Hanks

  • A Radiation Therapy Oncology Group (RTOG) phase III randomised study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas; first report of RTOG 9003

    K.K Fu;T.F Pajak;A Trotti;C.U Jones

Frequent Co-Authors

K. Kian Ang
K. Kian Ang The University of Texas MD Anderson Cancer Center
James F. Holland
James F. Holland Icahn School of Medicine at Mount Sinai
James D. Cox
James D. Cox The University of Texas MD Anderson Cancer Center
Arlene A. Forastiere
Arlene A. Forastiere Johns Hopkins University
Carlos A. Perez
Carlos A. Perez The University of Texas Health Science Center at Houston
Adam S. Garden
Adam S. Garden The University of Texas MD Anderson Cancer Center
David J. Grignon
David J. Grignon Indiana University
Morton Coleman
Morton Coleman Cornell University
Jean Bourhis
Jean Bourhis University of Lausanne
Ritsuko Komaki
Ritsuko Komaki The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those exploring alternatives to the traditional path of studying Medicine in the USA, online healthcare degrees offer flexible and accessible options. Students eager to fast-track their nursing education can consider 6 month lpn program online opportunities, which provide an accelerated route into practical nursing roles.

Specializations are also possible through online study. If you are interested in mental health, psych np online programs allow registered nurses to earn a graduate degree and qualify as advanced Psychiatric Mental Health Nurse Practitioners.

Beyond direct patient care, healthcare administration is another growing field. For aspiring healthcare leaders, the best online mha programs provide a convenient way to earn a master's in healthcare administration at reputable institutions. Those seeking to minimize tuition costs can explore options listed among the cheapest mha online programs.

Each of these academic paths can open doors to rewarding healthcare careers, whether you aim for clinical practice or leadership roles.

Best Scientists Citing Thomas F. Pajak

Trending Scientists